RA biologics comparison

Rheumatology

Compare biologic and targeted synthetic DMARDs for rheumatoid arthritis. After failing conventional DMARDs, patients have multiple biologic options. Choice depends on mechanism, route, insurance coverage, and individual risk factors.

Select any two to compare side by side

All products in this comparison

ProductManufacturerRouteFrequencyKey difference
HumiraAbbVieSC injectionEvery 2 weeksMost prescribed biologic for RA; extensive data; biosimilars available
EnbrelAmgenSC injectionWeeklyTNF receptor fusion protein; different mechanism than monoclonal antibody TNFi
OrenciaBMSIV infusion or SC injectionMonthly (IV) or weekly (SC)T-cell costimulation modulator; different mechanism than TNF inhibitors
KevzaraSanofi/RegeneronSC injectionEvery 2 weeksIL-6 receptor antagonist; effective as monotherapy (without methotrexate)
RinvoqAbbVieOral (tablet)DailyJAK inhibitor; oral; black-box warning limits to post-biologic failure
XeljanzPfizerOral (tablet)Twice daily or once daily (XR)First oral JAK inhibitor for RA; black-box warning
CimziaUCBSC injectionEvery 2–4 weeksPEGylated TNFi; no active placental transfer (preferred in pregnancy)
RemicadeJanssenIV infusionEvery 4–8 weeksIV TNFi; biosimilars widely available and often preferred by payers

Related guides

Denied one of these medications?

Ellen can decode your denial letter, identify why you were denied, and generate a personalized appeal, free for patients.